The Use of Recombinant Coagulation Factor VIIa (NovoSeven®) in Severe Diverticular Bleeding
نویسندگان
چکیده
منابع مشابه
The Use of Recombinant Coagulation Factor VIIa (NovoSeven ® ) in Severe Diverticular Bleeding
We report a 68-year-old man with sigmoid colon carcinoma who previously underwent an anterior resection. Five years later, he developed a severe diverticular bleeding which required multiple blood transfusions. He underwent an emergent low anterior colectomy with a right colostomy to protect the anastomosis. Nine days after the operation, he had another severe bleeding. Due to his elderly age a...
متن کاملFactor Viia (recombinant) (novoseven®) in Trauma
EVIDENCE DEFINITIONS • Class I: Prospective randomized controlled trial. • Class II: Prospective clinical study or retrospective analysis of reliable data. Includes observational, cohort, prevalence, or case control studies. • Class III: Retrospective study. Includes database or registry reviews, large series of case reports, expert opinion. • Technology assessment: A technology study which doe...
متن کاملUse of recombinant factor VIIa (NovoSeven) in pediatric cardiac surgery.
Significant post-operative bleeding can be encountered in a small population of pediatric surgical patients requiring cardiopulmonary bypass (CPB). Recombinant factor VIIa (NovoSeven) has been advocated as a possible off-label rescue therapy for these individuals when conventional blood component therapy alone is inadequate. This study retrospectively evaluates rFVIIa administration for the tre...
متن کاملTreatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven).
CARDIAC surgery with cardiopulmonary bypass (CPB) poses serious hemostatic challenges in Jehovah’s Witnesses, who refuse blood transfusions on religious grounds. Excessive bleeding ( 2 l) after cardiac surgery is encountered in 5–7% of Jehovah’s Witness patients, and necessitates reexploration in 3.6% of cases. Recombinant factor VIIa (rFVIIa, NovoSeven®; Novo Nordisk, Princeton, NJ), produced ...
متن کاملConsensus Recommendations for the Off-Label Use of Recombinant Human Factor VIIa (NovoSeven®) Therapy
ABSTRACT Objective: To rationalize decision-making concerning the growing and costly off-label use of recombinant human factor VII (rFVIIa, NovoSeven®) therapy. Options: Using rFVIIa therapy for patients with bleeding or providing usual care (e.g., continued clotting factor replacement). Outcome: Morbidity and mortality related to continued bleeding or thrombosis. Evidence: A literature review ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Open Surgery Journal
سال: 2008
ISSN: 1874-3005
DOI: 10.2174/1874300500802010001